YM BioSciences
New developments from YM BioSciences described
Published in Surgery Litigation and Law Weekly, November 24th, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at YM BioSciences.
Report 1: YM BioSciences Inc. (YMI) announced that its DELEX Therapeutics division has received the results of an interim analysis on the first 67 patients from its randomized, placebo-controlled phase 2b trial (DLXLEF-AP4) of AeroLEF for the treatment of moderate to severe acute pain in post-surgical patients.
The data indicated that AeroLEF provided benefit compared to placebo, however the difference between the treatment arm and placebo arm had not yet achieved the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
More Articles from Surgery Litigation and Law Weekly
- Business Update
Clinical and financial impact of eICU Program presented at American College of Chest Physicians - Personnel
HealthSouth names John P. Whittington general counsel and corporate secretary - Abdominal Aortic Aneurysms
Endologix announces favorable Powerlink five-year follow-up data at TCT 2006 Conference - Adverse Drug Reactions
New research on adverse drug reactions from John Radcliffe Hospital summarized - Aggressive Fibromatosis Therapy
Research on aggressive fibromatosis therapy described by scientists at National Taiwan University, Department of Otolaryngology - Allergy & Immunology
Key molecular signaling switch involved in an allergic disease is identified - More from this issue of Surgery Litigation and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
